The AHA appreciates the Medicare Payment Advisory Commission’s concerns about rising pharmaceutical costs and urged the Commission to continue to take action to achieve sustainable drug pricing. “Hospitals, and the clinicians who work in them, know firsthand the lifesaving potential of drug therapies … however, an unaffordable drug is not a lifesaving drug,” AHA said in a letter to MedPAC commissioners. AHA shared recommendations with MedPAC, including mandating an average sales price inflation cap for Medicare Part B and Part D drugs, and applying the cap to both high-cost and lower-cost drugs; identifying approaches to preventing excessively high launch prices as a response to an ASP inflation cap; maintaining the ASP plus 6 percent payment methodology for Part B drugs; testing a new Part D payment model that reduces or eliminates reinsurance payments while making appropriate adjustments to the direct subsidy rate; and improving annual public reports on Medicare Part B and Part D drug costs by making them more consumer and provider-friendly.

Related News Articles

Headline
The Government Accountability Office May 29 released a report recommending the Centers for Medicare & Medicaid Services target behavioral health services…
Headline
The Centers for Medicare & Medicaid Services May 21 announced it will immediately begin annual audits of all Medicare Advantage plans and work to clear a…
Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy…
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation…
Headline
The White House May 12 released an executive order to reduce prescription drug costs by allowing consumers to make direct purchases from drug manufacturers at…
Headline
Leaders from the Centers for Medicare & Medicaid Services at the 2025 AHA Annual Membership Meeting May 5 discussed issues on the agency’s agenda in a…